The highest efficacies were found in three β2AR agonists, metaproterenol, clenbuterol, and salbutamol, and, interestingly, in the drug riluzole which has been approved by the FDA for intervention in amyotrophic lateral sclerosis, where it was found to decrease dopaminergic degeneration in a PD rat model. The gene discussed is ADRB2; the disease is Parkinson disease.